INTERNATIONAL REMAP-CAP TRIAL SAYS INITIAL ANALYSIS SHOWS CONVALESCENT PLASMA DID NOT IMPROVE OUTCOMES FOR CRITICALLY ILL COVID-19 PATIENTS